Evidence map›Paper›PMID 41151836›Full record

ArticleJournal for immunotherapy of cancer2025

Genetic haplotypes in

Prithvi Raj, Jialiang Liu, Chengsong Zhu, Carlos Arana, Farjana J Fattah, Hong Mu-Mosley, Benjamin Switzer, Jason Y Park, Mitchell S von Itzstein, Edward K Wakeland and 7 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Prithvi RajDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, Texas, USA Prithvi.Raj@UTSouthwestern.edu.ORCID http://orcid.org/0000-0003-4068-4358
Jialiang LiuQuantitative Biomedical Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Chengsong ZhuDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Carlos AranaDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Farjana J FattahDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Hong Mu-MosleyHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Benjamin SwitzerDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.ORCID http://orcid.org/0000-0001-8150-1963
Jason Y ParkDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Mitchell S von ItzsteinHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Edward K WakelandDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Igor PuzanovDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.ORCID http://orcid.org/0000-0002-9803-3497
Yousef ZakhariaMayo Clinic Comprehensive Cancer Center, Phoenix, Arizona, USA.ORCID http://orcid.org/0000-0001-9480-2626
Gregory A DanielsDepartment of Medicine and Moores Cancer Center, University of California San Diego Health, San Diego, California, USA.
Montaser F ShaheenDivision of Hematology-Oncology and Mays Cancer Center, University of Texas Health Science Center, San Antonio, Texas, USA.
Yang XieQuantitative Biomedical Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Jeffrey A SoRelleDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
David E GerberHarold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID http://orcid.org/0000-0002-7812-6741

Funding

UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V. · 1996 to 2024
$57.4M
UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Kathryn Ann O'Donnell · 2010 to 2026
$53.7M
Finding the optimal balance of immunotherapy efficacy and toxicity.U01AI156189 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI GERBER, DAVID ERIC, WAKELAND, EDWARD K. · 2020 to 2024
$3.1M
NCI NIH HHS P30 CA142543NCI NIH HHS P50 CA070907NIAID NIH HHS U01 AI156189
6 · The paper itself

Abstract

backgroundImmune-related adverse events (irAEs) remain largely unpredictable, potentially affecting multiple organ systems and occurring at almost any point during and even occasionally after immune checkpoint inhibitor (ICI) treatment. To identify populations at risk for these immune-mediated toxicities, we analyzed genetic characteristics and immune markers associated with clinically significant irAEs.

methodsWe carried out a genome-wide association study on 373 white patients receiving ICI treatment. We identified single nucleotide polymorphisms associated with irAEs. Blood cytokine profiling and peripheral blood mononuclear cell RNA sequencing were performed at pretreatment baseline and 6-8 weeks after ICI initiation. Findings were validated in two external cohorts.

resultsWe identified genetic haplotypes in

conclusionsNovel polymorphisms in

Indexed as

ADAMTS9 ProteinImmune Checkpoint InhibitorsNeoplasmsAdultAgedFemaleGenome-Wide Association StudyHaplotypesHumansMaleMiddle AgedPolymorphism, Single NucleotideADAMTS9 ProteinADAMTS9 protein, humanImmune Checkpoint InhibitorsGeneticImmune related adverse event - irAE

Identifiers

PMID41151836
PMCPMC12570911

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.